New hope for babies with rare hormone disorder?
NCT ID NCT07187375
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the drug crinecerfont works in babies under 2 years old with congenital adrenal hyperplasia (CAH), a condition where the body can't make certain hormones properly. The goal is to measure drug levels in the blood and check for side effects. Only 7 infants are taking part, and they must already be on stable hormone treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neurocrine Clinical Site
Berlin, 13353, Germany
-
Neurocrine Clinical Site
Düsseldorf, 40225, Germany
-
Neurocrine Clinical Site
Heidelberg, 69120, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple saliva test replace blood draws for hormone monitoring?
- New program aims to smooth healthcare transition for teens with rare hormone disorder
- New hope for CAH: drug may slash steroid use
- New hope for toddlers with rare hormone disorder?
- Italian study checks how well newborn screening detects rare hormone disorder
- New hormone treatment shows promise for rare adrenal disorder